Accelerating AI-Driven Drug Development... National Institute for Korean Medicine Development and K-MediHub Sign MOU

AI-Based System to Accelerate the Scientific and Digital Advancement of Korean Medicine Technologies

The National Institute for Korean Medicine Development signed a memorandum of understanding (MOU) with K-MediHub on the 10th to accelerate new drug development based on artificial intelligence.

The National Institute for Korean Medicine Development signed a memorandum of understanding (MOU) with K-MediHub on the 10th to accelerate AI-based new drug development. Photo by the National Institute for Korean Medicine Development

Through this agreement, the two organizations plan to establish a collaborative system in various fields, including data sharing, platform integration, and the exchange of specialized technologies, as they seek new possibilities for drug development.

Specifically, they will pursue mutual advancement through sharing artificial intelligence technologies, generate outcomes by developing artificial intelligence models and connecting services, and lay the foundation for new drug development by supporting each other's research infrastructure.

Shin Jesu, Acting President of the National Institute for Korean Medicine Development, stated, "Through this agreement, we will combine the data and artificial intelligence technologies of both organizations to establish a foundation for drug development. We will also introduce artificial intelligence-based systems in the field of Korean medicine to promote the scientific and digital advancement of Korean medicine technologies."

The National Institute for Korean Medicine Development is currently developing artificial intelligence models to predict new efficacy, safety, and effectiveness for specific diseases, utilizing herbal medicine experimental data as a first step toward establishing an artificial intelligence platform for herbal medicine.